StockMarketWire.com - Benchmark has announced that operations at its state-of-the-art vaccine antigen production facility in Braintree, Essex, began on 29 Sep.

Benchmark said the £17m biotechnology building had processed its first commercial-scale batch of antigen, which would be used in a number of new aquaculture vaccines in Benchmark's product pipeline.

It said work on the final validation of the facility to ensure compliance with EU Good Manufacturing Practices (GMP) was under way and once fully licensed the increased capacity would allow the company to significantly expand the number and range of vaccines it produces.




Story provided by StockMarketWire.com